platelets

Phase 3Small molecule

LLeiden University Medical Center

platelets is one of 161 small molecule programs targeting Osteonecrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

ThrombocytopeniaActive, not recruiting

HemorrhageActive, not recruiting

Brain InjuryActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

OsteonecrosisPreclinical

Active, not recruiting

ThrombocytopeniaPreclinical

Active, not recruiting

HemorrhagePhase 3

Active, not recruiting

Brain InjuryPhase 2

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

245 competitors in Brain Injury

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 2

Zyloprim

Alnylam Pharmaceuticals

Phase 3

1 3

Brintellix

Takeda

Phase 3

1 4

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

5 5

Cyklokapron

AAmring

Phase 3

4 6

Nuvigil

NNuvo Research GmbH

Phase 3

2 7

Prometrium

Ferring

Phase 3

2 8

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 9

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Injury1 trial

Platelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01135862·100 enrolled

Thrombocytopenia1 trial

PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia

Completed·LLeiden University Medical Center··NCT06043050·1,042 enrolled

Intracerebral Hemorrhage1 trial

Platelet Transfusion in Acute Intracerebral Hemorrhage

Unknown status·UUniversity of Oulu·N/A·NCT00699621·100 enrolled

Osteonecrosis1 trial

Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis

Unknown status·—·N/A·NCT02721940·100 enrolled

Hemorrhage1 trial

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Completed·BBryan Cotton·Phase 3·NCT04704869·1,604 enrolled

1 more indication

Platelet Function1 trial

Platelet Function Analysis in Head Trauma: ASA/Plavix

Completed·—·N/A·NCT01534117·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for platelets. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — platelets compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for platelets. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLeiden University Medical Center

platelets

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Injury1 trial

Thrombocytopenia1 trial

Intracerebral Hemorrhage1 trial

Osteonecrosis1 trial

Hemorrhage1 trial

Platelet Function1 trial

References

Drug Info

Quick Facts

Related News